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Abstract
Pontocerebellar Hypoplasia (PCH) is group of very rare, inherited progressive neurodegenerative disorders with
prenatal onset. Up to now seven different subtypes have been reported (PCH1-7). The incidence of each subtype is
unknown. All subtypes share common characteristics, including hypoplasia/atrophy of cerebellum and pons,
progressive microcephaly, and variable cerebral involvement. Patients have severe cognitive and motor handicaps
and seizures are often reported. Treatment is only symptomatic and prognosis is poor, as most patients die during
infancy or childhood. The genetic basis of different subtypes has been elucidated, which makes prenatal testing
possible in families with mutations. Mutations in three tRNA splicing endonuclease subunit genes were found to
be responsible for PCH2, PCH4 and PCH5. Mutations in the nuclear encoded mitochondrial arginyl- tRNA
synthetase gene underlie PCH6. The tRNA splicing endonuclease, the mitochondrial arginyl- tRNA synthetase and
the vaccinia related kinase1 are mutated in the minority of PCH1 cases. These genes are involved in essential
processes in protein synthesis in general and tRNA processing in particular. In this review we describe the
neuroradiological, neuropathological, clinical and genetic features of the different PCH subtypes and we report on
in vitro and in vivo studies on the tRNA splicing endonuclease and mitochondrial arginyl-tRNA synthetase and
discuss their relation to pontocerebellar hypoplasia.
Review
Pontocerebellar Hypoplasias
The name Pontocerebellar Hypoplasia (PCH) originates
from a report of Brun almost a century ago, in which he
described human brain development and abnormalities
associated with brain development. Cerebellar Hypopla-
sia is described as dwarfed growth of the cerebellum [1].
Seven years later Brouwer suggested that pontocerebel-
lar hypoplasia is possibly due to degeneration rather
than to hypoplasia [2]. Subsequent reports described the
pathology as atrophy of cerebellar hemispheres with
relative sparing of the flocculi and vermis and apparent
fragmentation of the cerebellar dentate nucleus [3-5].
The first reported case of PCH which included specific
clinical details was probably by Krause [4]. He reported
a child with swallowing problems, spasticity and com-
plete absence of cognitive and voluntary motor develop-
ment with the pathological profile of PCH. In retrospect
t h i sm a yh a v eb e e nt h ef i r s td o c u m e n t e dc a s eo nP C H
type 2. Pfeiffer and Pfeiffer first reported the extrapyra-
midal component [5-8]. Barth et al. described a cluster
of related families with PCH from a genetic isolate in
the Netherlands as an inherited syndrome of microce-
phaly, dyskinesia and pontocerebellar hypoplasia [9]. A
first attempt for classification was based on two sub-
types; this divided PCH in cases with accompanying
spinal anterior horn disease (type 1) and cases with
chorea/dyskinesia (type 2) [10]. This classification was
extended into five subtypes in 2006 and in 2007 a sixth
was added [11,12]. The latest subtype that may be classi-
fied as PCH7, has been recently added to this list [13].
PCH now includes seven (PCH1-7) disorders. In most
cases, especially in PCH1, PCH2, PCH4 and PCH5 pre-
natal onset of structural decline is well documented. In
some milder cases cerebellar images suggest a perinatal
or early postnatal onset. The clinical diagnosis is made
on neuroradiological, neuropathological and neurologi-
cal findings [14-18]. Neuroradiological findings in all
subtypes are pontocerebellar hypoplasia and atrophy of
ventral pons, cerebellum and to a lesser extent also the
cerebral cortex (Figure 1). Neuropathologically, there is
segmental degeneration of the cerebellar cortex with
* Correspondence: f.baas@amc.uva.nl
1Department of Genome Analysis, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Full list of author information is available at the end of the article
Namavar et al. Orphanet Journal of Rare Diseases 2011, 6:50
http://www.ojrd.com/content/6/1/50
© 2011 Namavar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.loss of Purkinje cells, fragmentation of the dentate
nucleus and degeneration with neuronal loss and
decreased folding of the inferior olivary nuclei in PCH1,
PCH2, PCH4 and PCH5. Neuropathological studies in
the other types are scarce or absent. Cerebellar hemi-
spheres are usually more severely affected than the ver-
mis and there is progressive loss of the ventral nuclei
and transverse fibers in the pons [19]. Furthermore
there is severe progressive microcephaly and variable
ventriculomegaly. Severe intellectual deficit, swallowing
problems and seizures are clinical features of all sub-
types [9,18,20].
Clinical features of the PCH subtypes
PCH1
PCH type 1 (Table 1) (PCH1, previously known as Nor-
man’s disease, ORPHA2254, MIM 607596) is character-
ized by pontocerebellar hypoplasia with additional loss
Figure 1 MRI sections of cases with PCH type 1, type 2 and type 4. The images of the PCH1 case were kindly provided by Professor Darin,
The Queen Silvia. Children’s Hospital, Gothenburg University, Sweden. 1A-C: Images of a 2 wk old neonate with PCH1. 1A: Mid-sagittal section
(T1) shows vermal hypoplasia and marked cerebellar hypoplasia. 1B: Lateral sagittal section (T1) shows severe hypoplasia of the cerebellar
hemispheres. 1C: Coronal section (T2) shows flattened cerebellar hemispheres which also display some atrophy. The vermis is relatively spared.
1D-E: Images of a 2 months old baby with PCH2. 1D: Mid-sagittal section (T1IR) shows a flat ventral pons and vermal hypoplasia. 1E: Lateral
sagittal section (T1IR) shows severely hypoplastic cerebellar hemispheres (arrow) leaving most of the posterior fossa empty. 1F: Coronal section
(T2) of a 9 months old infant with PCH2 shows flat cerebellar hemispheres and mild vermal hypoplasia (dragonfly configuration). Cerebral
cortical atrophy is also present. 1G-I: Images of a 31+5 weeks neonate with PCH4. 1G: Mid-sagittal section (T2) shows severe vermal hypoplasia
and ventral pontine flattening. 1H: Lateral sagittal section (T2) shows severe hypoplasia of the cerebellar hemispheres. Above the tentorium
there is an increased distance between the cortical surface and the skull visible, which is probably due to diminished brain growth in utero. 1I:
Coronal section (T1) shows extremely small and flattened cerebellar hemispheres and severe vermal hypoplasia. Immaturity of cerebral cortex
and enlarged ventricles are also visible.
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PCH Clinical features Pathological features Gene(s) Ref.
PCH1 Neonatal period: Hypotonia, impaired
swallowing, congenital contractures
and/or polyhydramnios, primary
hypoventilation, progressive
microcephaly.
MRI: Pontocerebellar hypoplasia.
Cerebellar hypoplasia: hemispheres > >
vermis, areas of stunted or absent folial
development. Cerebellar dentate nucleus
present as tiny remnants.
Olivary nucleus: absent folding and
gliosis.
Pons: loss of ventral nuclei and
transverse fibers.
Spinal cord: Anterior horn cell
degeneration.
Peripheral nerves and muscle: chronic
denervation.
One family with the common TSEN54
mutation.
One case with missense plus splice
site mutations in RARS2.
One atypical mild family with
nonsense mutations in VRK1.
Locus unknown in the majority.
[6,7,10,20,21,40,42]
PCH2 Neonatal period: Clonus, impaired
swallowing.
Infancy and later: Chorea, variable
spastic pareses; progressive
microcephaly. Severe impairment of
cognitive and motor development.
MRI: Variable neocortical atrophy,
pontocerebellar hypoplasia.
Cerebellar hypoplasia: hemispheres > >
vermis. Segmental degeneration of
cerebellar cortex. Fragmentation of
cerebellar dentate nucleus.
Olivary nucleus: neuron loss and
decreased folding.
Pons: progressive loss of ventral nuclei
and transverse fibers.
Cerebral cortex: progressive atrophy
TSEN54: p.A307S, A307S most common
in 75 families.
Rarely: Other TSEN54 missense
mutations in 3 families, TSEN2
mutations in 2 families, TSEN34
mutations in 1 family.
[15,18-20,28,37]
PCH3 Neonatal period: Hypotonia, impaired
swallowing.
Infancy and later: Short stature
progressive microcephaly, optic
atrophy.
MRI: Neocortical and cerebellar
atrophy, pontocerebellar hypoplasia;
Pons and cerebellum equally affected.
No autopsies performed. Locus on chromosome 7 q in 2
families.
[30-32]
PCH4 Neonatal period: Hypertonia, severe
clonus, polyhydramnios and/or
contractures; primary hypoventilation.
MRI: Delayed neocortical maturation,
pontocerebellar hypoplasia;
microcephaly on autopsy.
Cerebellar hypoplasia: hemispheres > >
vermis, areas of stunted or absent folial
development. Cerebellar dentate nucleus
present as tiny remnants
Olivary nucleus: absent folding and
gliosis.
Pons: loss of ventral nuclei and
transverse fibers.
TSEN54: Compound heterozygosity for
p.A307S plus nonsense or splice site
mutations in 10 families. Three
missense mutations in 1 family.
[14,16,19,20,37]
PCH5 Prenatal/neonatal period: Clonus or
seizures.
Neonatal period: Persistent clonus,
microcephaly and pontocerebellar
hypoplasia on autopsy.
Cerebellar hypoplasia: cortical
involvement as in PCH4, but vermal
cortex more extensively affected than
hemispheric cortex; subtotal loss of
cerebellar dentate nucleus.
Olivary nucleus: absent folding.
Pons: loss of ventral nuclei and
transverse fibers.
TSEN54: Compound heterozygosity
for p.A307S plus splice site mutation
in 1 family.
[11,20]
PCH6 Neonatal period: Hypotonia, clonus,
impaired swallowing.
Infancy and later: Progressive
microcephaly, spasticity, elevated CSF
lactate, edema of extremities.
MRI: Neocortical and cerebellar
atrophy, pontocerebellar hypoplasia;
Pons and cerebellum equally affected.
No autopsies performed. Missense and splice site mutations in
RARS2 in 2 families.
[12,39]
PCH7 Neonatal period: No palpable gonads
with a micropenis. Hypotonia.
Infancy and later: Regression of penis.
Progressive microcephaly, seizures,
respiratory distress, poor feeding.
MRI: Pontocerebellar hypoplasia.
Cerebellar hypoplasia: absence of
cerebellar hemispheres with neuronal
loss.
Olivary nucleus: absent.
Pons: loss of ventral nuclei and
transverse fibers.
Cerebral cortex: progressive atrophy.
No locus. [13]
Adapted and extended from Namavar et al. [38].
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cord, pathologically similar to the spinal muscular atro-
phies (SMA) [6,7]. Magnetic resonance imaging (MRI)
of PCH1 patients always shows cerebellar hypoplasia in
which the cerebellar hemispheres are variably affected;
in some cases more flat and in other cases more pre-
served (Figure 1A-C). There is variable involvement of
pons and cerebrum [21]. Patients suffer from severe
hypotonia, pareses, central visual failure, dysphagia,
respiratory insufficiency, psychomotor retardation and
they usually die within the first year. The majority of
patients also exhibits prenatal onset of symptoms such
as congenital contractures and polyhydramnios. Micro-
cephaly in most reported cases is not present at birth,
but develops postnatally [7,10,21-25].
PCH2
PCH type 2 (PCH2, ORPHA2524, MIM 277470, 612389,
612390) is the most frequently reported and therefore
the best studied subtype (Table 1) [10,18-20,26]. So far
at least 81 families have been reported [20,27,28]. Extra-
pyramidal dyskinesias and dystonia are the major fea-
tures of PCH2, pure spasticity is reported in a minority.
Other clinical features include impairment of swallowing
from birth on, jitteriness in the neonatal period, central
visual failure and seizures. There is no involvement of
the spinal anterior horn cells in any of the cases that
have been studied post-mortem. Life expectancy is
unpredictable, as age of death ranges from the neonatal
period to well into adulthood; most patients however do
not reach puberty [20]. Recently chances for survival
have become greater due to improved care, such as tube
feeding and gastrostomy. Typical brain MRI findings are
a dragonfly-like cerebellar pattern on coronal sections,
in which the cerebellar hemispheres are flat and severely
reduced in size and the vermis is relatively spared
(Figure 1D, E, F) [20]. Mild or severe atrophy of the cer-
ebral cortex is observed in 40% of the PCH2 cases. On
MRI myelination is delayed, but demyelination has not
been observed [20].
Prenatal diagnosis by ultrasound imaging is not yet
possible in the second trimester of pregnancy, therefore
molecular genetic testing is required for prenatal diag-
nosis in high risk pregnancies [29].
PCH3
PCH type 3 (PCH3, ORPHA97249, MIM 608027) also
known as cerebellar atrophy with progressive microce-
p h a l y( C L A M ) ,i sav e r yr a r es u b t y p eo fP C H( T a b l e1 ) .
Only three families have been described so far. All cases
had short stature, seizures, hypotonia and in four of the
five cases optic atrophy was reported [30-32]. In the
most recent reported case, the patient suffered from an
additional severe Vitamin A deficiency with unknown
cause [32].
PCH4
PCH type 4 (PCH4, olivopontocerebellar hypoplasia
(OPCH), ORPHA166063, MIM 225753) shares similari-
ties with PCH2; however PCH4 is more rare and the dis-
ease course is more severe (Table 1). Up to now 18
families have been reported with a PCH4 phenotype
[14,16,20,28,33-36]. Patients exhibit more severe perina-
t a ls y m p t o m ss u c ha se x c e s s i v e ,p r o l o n g e dg e n e r a l
clonus, congenital contractures, polyhydramnios and pri-
mary hypoventilation the latter necessitating prolonged
mechanical ventilation. Weaning from ventilatory sup-
port is often impossible making survival through the neo-
natal period exceptional [20]. The pathology seen in
PCH4 deviates in some regards from PCH2. A striking
pathological distinction in PCH4 is the C-shaped form of
the inferior olives and large denuded areas without folia
in the cerebellar hemispheric cortex, both phenomena
suggesting an early prenatal onset [14,19,37]. Other strik-
ing features in PCH4 are pericerebral cerebrospinal fluid
(CSF) accumulation, wide midline cava and delayed neo-
cortical maturation; all suggesting prenatal decline of cer-
ebral growth. Additionally the cerebellar vermis is more
severely affected (Figure 1G, H, I) [20,38]. MRI analysis is
therefore helpful in the clinical diagnosis of PCH4.
PCH5
Only one family with PCH type 5 (PCH5,
ORPHA166068, MIM 610204) has been described
(Table 1). In this subtype of PCH, patients displayed
fetal onset of seizure-like activity in combination with
severe olivopontocerebellar hypoplasia and a severely
affected cerebellar vermis [11]. Autopsy of the three
published siblings showed diffuse brain volume loss, C-
shaped inferior olivary nuclei, absent or immature den-
tate nuclei and cell death which was more pronounced
in the cerebellar vermis than in the hemispheres. No
evidence was found for spinal cord involvement.
In retrospect there is an arbitrary difference between
PCH4 and PCH5 [38]. In PCH5 the vermis was more
affected than the hemispheres, whereas in PCH4 the
vermis and the hemispheres are both severely affected,
with the emphasis on the hemispheres. The prenatal sei-
zure-like activity observed in PCH5 appears similar to
the severe neonatal clonus observed in PCH4 [16]. The
primary hypoventilation observed in PCH5 is also a typi-
cal aspect of PCH4 [20].
PCH6
PCH type 6 (PCH6, ORPHA166073, MIM 611523) is a
rare subtype of PCH (Table 1). The first published
family with PCH6 is a Sephardic Jewish family with
three siblings exhibiting cerebellar and vermal hypopla-
sia, infantile encephalopathy, dysphagia, seizures, pro-
gressive microcephaly and generalized hypotonia
followed by spasticity [12]. No developmental milestones
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drial complexes showed reduced activity of mitochon-
drial complexes I, III, and IV in muscle, while activity of
complex II was normal. Elevated CSF lactate levels were
found. Another case by Rankin et al.w i t haP C H 6p h e -
notype in combination with progressive encephalopathy
and edema, was suggestive of PEHO syndrome (Progres-
sive Encephalopathy with Oedema, Hypsarrhythmia and
Optic atrophy) [39]. No autopsies have been performed
in PCH6 cases so far.
PCH7
A new subtype was proposed based on a profile combining
genital abnormalities in combination with PCH. We tenta-
tively classify this as PCH7 (Table 1). The male patient
had impalpable testes with a micropenis at birth and an
XY karyotype. In the following weeks he developed pro-
gressive microcephaly, swallowing problems, hypotonia,
respiratory distress, absent tracking movements, a head lag
and seizures. MRI at the age of 16 weeks showed ponto-
cerebellar hypoplasia and cerebral atrophy. At 19 weeks of
age, regression of penile corporeal tissue was noted. He
died at 5 1/2 months of age [13].
Genetics of PCH
TSEN-related PCH and genotype-phenotype correlations
Through homozygosity mapping in a cluster of related
families with PCH2, the genetic basis for PCH2 was
identified [37]. All patients were homozygous mutant
for an amino acid change of an alanine into a serine at
position 307 (p.A307S, common mutation) in the trans-
ferRNA (tRNA) splicing endonuclease subunit 54 gene
(TSEN54) (Table 2). Ninety percent of the well-defined
PCH2 cases carried this mutation [37]. This TSEN54
mutation correlated strongly with jitteriness, clonus,
dyskinesia and/or dystonia and with flat cerebellar hemi-
spheres on coronal MRI compared to those PCH cases
where no mutation was identified (Figure 1F) [20].
In rare occasions, mutations are found in two of the
three other subunit genes of the tRNA splicing endonu-
clease, TSEN2 and TSEN34 (Table 2) [20,37]. Four
patients have been described so far; three with TSEN2
mutations and one with a TSEN34 mutation [20]. These
cases have a PCH2 phenotype, as they exhibited spasti-
city and/or dyskinesias. Other missense mutations than
the p.A307S in TSEN54, have been associated with
PCH2 as well (Table 2). Some of these patients with a
rare mutation in TSEN54 and the patient with a
TSEN34 mutation have relatively mild involvement of
pons and cerebellum. On early coronal MRI the cerebel-
lar hemispheres are not completely flat, but fill the pos-
terior fossa almost completely, suggestive of postnatal
a t r o p h yr a t h e rt h a nh y p o p l a s i a[ 2 0 ] .B e c a u s eo n l yaf e w
patients with TSEN2, TSEN34 and rare TSEN54 mis-
sense mutations other than p.A307S have been
Table 2 Pathogenic mutations in PCH.
Gene Nucleotide position Protein position Subtype
TSEN54 c.178_215del p.E60AfsX109 PCH4
TSEN54 c.285G > C p.A95A Splice site mutation PCH4
TSEN54 c.277T > C p.S93P PCH4
TSEN54 c.371G > T p.G124V PCH2
TSEN54 c.370-2A > G p.G124_Q138del PCH4
TSEN54 c.468+2T > C Splice site mutation PCH5
TSEN54 c.736C > T p.Q246X PCH4
TSEN54 c.919G > T p.A307S (common) PCH1, PCH2, PCH4, PCH5
TSEN54 c.953delC p.P318QfsX23 PCH4
TSEN54 c.1027C > T p.Q343X PCH4
TSEN54 c.1056_1057del p.R353GfsX81 PCH4
TSEN54 c.1170_1183del p. V390fsX39 PCH4
TSEN54 c.1251A > G p.P417P Splice site mutation PCH4
TSEN54 c.1430+2T > A Splice site mutation PCH4
TSEN54 c.1537T > G p.Y513D PCH4
TSEN34 c.172C > T p.R58W PCH2
TSEN2 c.926A > G p.Y309C PCH2
TSEN2 c.960+1delGTAAG Splice site mutation PCH2
RARS2 c.35A > G p.Q12R PCH1, PCH6
RARS2 c.110+5A > G Splice site mutation PCH1, PCH6
RARS2 c.1024A > G p.M342V PCH6
VRK1 c.1072C > T p.R358X PCH1
Note that in PCH4 and PCH5 there is compound heterozygosity for a nonsense or a splice site mutation plus a missense mutation (p.A307S, TSEN54).
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izations about their phenotypes.
Whereas missense mutations in TSEN54 underlie
PCH2, heterozygous missense- plus heterozygous non-
sense or splice site mutations in TSEN54 underlie the
more severe PCH4 (Table 1 Table 2) [20,27,37]. In one
case, three TSEN54 missense mutations were found in
PCH4. This case was homozygous mutant for the com-
mon mutation, plus another missense mutation (p.S93P)
on one of the alleles, giving rise to a PCH4 phenotype.
Nonsense and splice site mutations in TSEN54 are asso-
ciated with increased severity of hypoplasia of pons and
cerebellum and immaturity of the cerebral cortex with
more perinatal symptoms and an earlier lethality than
seen in PCH2.
As in PCH4, a heterozygous missense mutation (p.
A307S) plus a heterozygous splice site mutation (c.468
+2T > C) in TSEN54 has been found to be responsible
for PCH5 (Table 2) [38]. Although milder, the clinical
findings in PCH2 are similar to PCH4 and PCH5.
Therefore PCH5, PCH4 and PCH2 represent a spectrum
of clinical manifestations caused by different mutations
in the TSEN genes (Table 1). It is still unclear whether
PCH1 is part of this spectrum too, as the common
mutation in TSEN54 was identified in one case from a
family with three siblings with a PCH1 phenotype [40].
DNA was only available in one of the three siblings.
Post-mortem examination revealed neuronal cell loss of
the anterior horns of the cervical cord [40]. PCH1
seems to be more heterogeneous than PCH2/PCH4 and
several genes are already involved in the minority of the
PCH1 cases.
Reliable estimations of the incidence of the common/
p.A307S mutation (TSEN54) are difficult to obtain.
Although PCH2 with this underlying mutation is the
most common form of PCH, it is still a rare disease and
clusters in isolated communities. In the Dutch and Ger-
m a np o p u l a t i o nt h ec a r r i e rf r e q u e n c yo ft h ec o m m o n
mutation is 0.004 [37]. With 184 915 newborns in the
Netherlands in the year 2009 one would expect 3
affected children per annum [41]. However, since the p.
A307S mutation occurs in closed communities, where
consanguinity occurs, probably more affected children
are born per year, than one would expect based on car-
rier frequency in unrelated Caucasian individuals.
Therefore preconceptional testing with prenatal diagno-
sis for this disease in selected regions is advised.
RARS2-related PCH
Following homozygosity mapping in the first published
PCH6 family, a homozygous intronic splice site muta-
tion (c.110+5A > G) was found in the gene for the
nuclear encoded mitochondrial arginyl-tRNA synthetase
(RARS2) (Table 2) [12]. A second PCH6 case with addi-
tional progressive encephalopathy and edema was
compound heterozygote for RARS2 missense mutations
(Table 2) [39].
Mutations in RARS2 were identified in one case with a
PCH1 phenotype [20]. Although this case had high CSF
lactate levels, which is normally not reported in PCH1,
post-mortem examination revealed a neuropathological
profile that fits a PCH1 phenotype with loss of spinal
anterior horn neurons.
Other genes and loci involved in PCH
Nonsense mutations in the Vaccinia Related Kinase1
gene (VRK1) were reported to be associated with
pontocerebellar hypoplasia plus SMA in one atypical
PCH1 family of Ashkenazi Jewish origin [42]. Despite
the severe microcephaly at birth (fronto-occipital cir-
cumference -3SD and -6SD), the three affected chil-
dren were mildly delayed in their developmental
milestones. The proband was e.g. able to walk at the
age of 3 years; however she became wheelchair bound
later in life and eventually died at the age of 11 years.
Cognitive impairment was stated as mild mental
retardation, whereas in typical PCH1 cases there is
severe mental retardation and no developmental
milestones will be achieved [7,10,21-25]. Up to now
no other cases with VRK1 mutations have been
reported.
Mutations or deletions in the survival motor neuron
gene (SMN1)c a u s eS M A .I nP C H 1l i n k a g et ot h eSMN
genes has been excluded; although the motor neuron
loss observed in PCH1 is morphologically similar to the
motor neuron loss in SMA [43,44]. There is no locus
for the majority of the PCH1 cases and no other genes
have been linked to PCH1 yet, with the exception of
rare cases with TSEN54, RARS2 and VRK1 mutations
(Table 2). Fifteen families with a PCH1 phenotype have
been published thus far; only in 3 families mutations
were identified [6,7,10,20-25,34,40,42,44-51]. Further
research on these and other candidate genes in PCH1 is
necessary to identify mutations involved in the remain-
ing majority of the PCH1 cases.
Linkage on chromosome 7 q was found in two of the
three families with PCH3, but no causative gene has
been found [30,31]. Unfortunately no linkage analysis
was performed in the most recently published case with
PCH3 [32].
There is no locus yet for PCH7, however sequencing
of the coding regions in TSEN54, TSEN34, TSEN2,
TSEN15 and RARS2 yielded no mutations. FISH analysis
of SRY and Xq12 and a CGH-array appeared to be nor-
mal, as well as ARX expansion analysis [13].
Management and Treatment
There is no cure for PCH: Management is only sympto-
matic and includes nutritional support by percutaneous
endoscopic gastrostomy (PEG feeding), treatment of
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tory support is provided. The chorea in PCH2 is difficult
to treat, but physiotherapy may ease cases with severe
dystonia or spasticity. Levodopa treatment appeared
beneficial in some cases [52].
Life-threatening complications of PCH are cot death,
sleep apnea and malignant hyperthermia with rhabdo-
myolysis with extreme elevation of plasma creatine
kinase. Sleep apnea can be detected by sleep monitoring.
Malignant hyperthermia should be prevented by suffi-
cient hydration and monitoring especially during periods
of infection [26].
Other diseases with (ponto)cerebellar hypoplasia
There are several other diseases that one may consider
when a patient presents with pontocerebellar hypoplasia,
see also Table 3 for an indication.
Genetic diseases with cerebellar hypoplasia and/or atrophy
and variable cerebral cortical atrophy
Recently a new PCH-like phenotype has been described:
Progressive Cerebello-Cereberal Atrophy (PCCA).
Patients with PCCA have postnatal atrophy of the cere-
bellar hemispheres, which is not typical for PCH, but
some PCH patients do have this feature [20,30]. Patients
with PCCA have progressive microcephaly, severe spas-
ticity, mental retardation and in some cases seizures.
Sequential brain MRI of patients shows the progressive
nature of the cerebellar and cerebral atrophy. Missense
mutations in the O-phosphoseryl-tRNA selenocysteine
tRNA synthase gene (SEPSECS) are associated with this
disease (Table 3) [53].
In infantile cerebral and cerebellar atrophy (ICCA)
there is also cerebellar volume loss with psychomotor
retardation, seizures, jitteriness, clonus, severe spasticity,
Table 3 Differential diagnostic options for PCH.
Differential diagnosis Cerebellar Hypoplasia plus: Gene(s) Pathways involved Key
references
Genetic diseases with cerebellar hypoplasia and/or atrophy and variable cerebral cortical atrophy
PCCA Progressive Cerebello-cerebral atrophy,
progressive microcephaly, spasticity, seizures,
mental retardation and seizures.
Missense
mutations in
SEPSECS.
Selenocysteine synthesis [53]
ICCA Severe atrophy of cerebrum and cerebellum.
Psychomotor retardation, clonus, seizures,
spasticity, progressive microcephaly.
Missense
mutations in
MED17
Transcripition initiation [54]
CDG type 1A and 1D Hypotonia, ataxia, developmental delay, failure
to thrive, microcephaly.
PMM2
(type1a), ALG3
(type 1d)
Glycoprotein biosynthesis [55,56]
Phosphoserine aminotransferase
deficiency
Low CSF concentrations of serine and glycine,
seizures, progressive microcephaly, hypertonia
and psychomotor retardation. White matter
immaturity and cerebral atrophy.
PSAT Serine biosynthesis [59]
Different congenital mitochondrial
disorders
Respiratory chain deficiencies plus several other
abnormalities.
- n/a [60]
PEHO-syndrome Progressive cerebellar atrophy, progressive
encephalopathy, hypsarrythmie, edema and
optic atrophy.
Unknown Unknown [62,63]
Genetic diseases with cerebellar hypoplasia plus neocortical dysplasia
Dystroglanopathies: Walker-
Warburg syndrome, MEB-disease,
Fukuyama
Neocortical dysplasia. Mental retardation, eye
abnormalities, seizures, impaired motor control.
FKRP, LARGE,
POMGNT1,
POMT1,
POMT2, FKTN
Dystroglycan synthesis [64,65]
Lissencephaly Lissencephaly phenotype. RELN Neuronal migration [67]
X-linked brain malformation
phenotype with microcephaly and
hypoplasia of the brainstem and
cerebellum
Microcephaly, optic atrophy, sensorineural
hearing loss, simplified gyri, developmental
delay.
CASK Neuronal migration; Part of
MAGUK protein family, involved
in signaling in both, pre- and
post-synapses.
[66]
Congenital fibrosis of the
extraocular muscles 3 with
extraocular involvement
Ocular motility disorder, facial weakness, axonal
peripheral neuropathy, delayed development,
neocortical dysplasia and other neuronal
migration disorders.
TUBB3 Neuronal migration [68,69]
Acquired cerebellar hypoplasia
Extreme prematurity (< 32 weeks) Extreme prematurity. n/a n/a [70]
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Page 7 of 14visual problems, hypertonia and progressive postnatal
microcephaly. Brain MRI shows severe atrophy of cere-
brum and cerebellum (Table 3) [54].
Certain subtypes of the congenital disorders of glyco-
sylation (CDG) disorders manifest with cerebellar hypo-
plasia as well. CDG-1a patients have generalized
hypotonia, developmental delay, swallowing problems,
failure to thrive and cerebellarh y p o p l a s i a ,n e x tt ov a r i -
able external dysmorphia and hematologic problems
[55]. Cerebellar hypoplasia is also present in patients
with CDG-1d, a rare form of CDG (Table 3) [56-58].
Phosphoserine aminotransferase deficiency is asso-
ciated with low CSF concentrations of serine and gly-
cine. Clinically patients exhibit seizures, progressive
microcephaly, hypertonia and psychomotor retardation.
MRI shows cerebral atrophy, poor white matter develop-
ment and vermal hypoplasia. The authors did not men-
tion the size and morphology of the cerebellar
hemispheres (Table 3) [59]. Also in various pediatric
mitochondrial disorders predominant cerebellar volume
loss is relatively common, together with respiratory
chain deficiencies (Table 3) [60,61]. Progressive cerebel-
lar atrophy is commonly found in patients with PEHO-
syndrome (Table 3) [62,63].
Genetic diseases with cerebellar hypoplasia plus neocortical
dysplasia
Dystroglycanopathies cause neocortical dysplasia and
variable pontocerebellar hypoplasia and microcephaly or
hydrocephalus (Table 3) [64,65]. An X-linked brain mal-
formation phenotype with a moderately simplified gyral
pattern and mild cortical dysplasia, only visible on
autopsy is due to mutations in the calcium/calmodulin
dependent serine protein kinase gene (CASK). It can
manifests with microcephaly, optic atrophy, sensori-
neural hearing loss and pontocerebellar hypoplasia
(Table 3) [66]. Other diseases with cerebellar hypoplasia
and additional neocortical dysplasia but easier to differ-
entiate from PCH, are lissencephaly with agyria or very
wide gyria and congenital fibrosis of the extraocular
muscles type 3 (CFEOM3) with extraocular involvement
like neocortical dysplasia and neuronal migration defects
(Table 3) [67-69].
Acquired cerebellar hypoplasia
Extreme prematurity (< 32 weeks) in infants can also
lead to cerebellar hypoplasia, due to disruption of nor-
mal brain development. One should be aware of this
when a prematurely born neonate presents with these
features (Table 3) [70,71].
Pathogenesis
The function of the tRNA splicing endonuclease
The tRNA splicing endonuclease (TSEN) complex is
mutated in the majority of the PCH cases. The endonu-
clease complex is encoded by four different TSEN genes
(TSEN2, 15, 34, 54) and consists of four protein subu-
nits. Together they form one heterotetramic enzyme,
consisting of two catalytic subunits (TSEN2 and
TSEN34) and two structural subunits (TSEN54 and
TSEN15) [72-74]. In mammals, maturation of tRNA
necessitates removal of the 5’ leader and 3’ trailer
sequences, addition of a CCA tail and various modifica-
tions [75]. Six percent of the human tRNA genes are
intron-containing; this intron is not removed by the
conventional splicing machinery, but by the TSEN com-
plex. Only these intron-containing tRNAs require the
TSEN complex for excising the tRNA into two halves;
one 5’tRNA half with a 2’-3’ cyclic phosphate at the
cleavage site and a 3’tRNA half with a 5’OH-group at
the other cleavage site (Figure 2A). The individual
halves of the tRNA are ligated together again. Mature
tRNAs are essential for translation of messengerRNA
(mRNA) into proteins, as they transfer the correct
amino acid to the ribosome to incorporate these amino
acids at the growing peptide chain. Each amino acid has
its own cognate tRNA and each tRNA has an anticodon
sequence that can interact to the corresponding codon
on mRNA sequence. In humans there are 506 different
tRNA genes, meaning that there are more tRNA genes
than codons. For certain tRNA species the majority of
the tRNA genes are intron-containing: For example, 13
of the 14 tRNA-Tyr (GTA) genes contain an intron
(Table 4). For other tRNAs there are no intron-contain-
ing tRNA genes at all: For example all tRNA-Gly (GCC,
CCC, TCC) genes are not intron-containing. For further
information on intron-containing and intronless tRNA
genes, see [76].
The TSEN complex is not only involved in tRNA spli-
cing, it is also involved in mRNA 3’end formation.
Knockdown of TSEN2 results in impaired mRNA 3’end
formation of two housekeeping transcripts GAPDH and
EF1A mRNA in HEK293 cells [73]. Furthermore the
TSEN complex interacts with a lot of factors associated
with the mRNA 3’end processing machinery [73,77].
In 2007, the human cleavage and polyadenylation fac-
tor I subunit (hClp1) was identified as siRNA kinase.
hClp1 is a binding partner of the TSEN complex and its
kinase activity is also active on 3’tRNA halves, further-
more hClp1 participates in mRNA 3’end formation
[78-80]. It seems that multiple enzymes involved in
RNA processing assemble into a molecular equivalent of
a ‘Swiss Army Knife’, creating a complex that can cleave
and process several different RNA species [79].
The TSEN complex and PCH
In vitro studies of the TSEN complex In 2006 the yeast
Sen complex was purified and different mutations in the
complex were introduced; this showed that certain
mutations abolished tRNA splicing activity whereas
others do not affect tRNA splicing at all [74]. The
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Page 8 of 14Figure 2 Different RNA processing events in mammals. 2A: Eukaryotic splicing pathway of tRNA splicing in mammals. The TSEN complex is
involved in the maturation of premature tRNAs and excises the tRNA into two halves; one 5’tRNA half with a 2’-3’ cyclic phosphate at one exon-
end and a 3’tRNA half with a 5’OH-group at the other exon-end. The final processing of tRNA maturation involves either direct ligation of the
two tRNA halves by ligation through the Archaea-like pathway (by HSPC117, depicted) or indirect ligation through the yeast-like pathway (not
depicted) [104]. Adapted from Calvin et al. [105]. 2B: tRNA aminoacylation in mammals. RARS2 can bind to its cognate amino acid in an ATP
dependent matter. This complex of ATP, RARS2 and arginine binds to the mt-tRNA-Arg and arginine will be transferred to its tRNA. Adapted
from Antonellis et al. [83]. 2C: Selenocysteine synthesis. Serine (Ser) is aminoacylated to tRNA-Sec by a seryl-tRNA synthetase (SARS). This Ser-
tRNA-Sec complex is then converted by a kinase to a Sep-tRNA-Sec complex. In the presence of the cofactor pyridoxal phosphate (PLP) and the
selenium donor selenophosphate (Se-donor) the SEPSECS enzyme converts the Sep-tRNA-Sec to Sec-tRNA-Sec. Adapted from Allmang et al. [87].
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Page 9 of 14authors also show that the same mutation can have a
different effect on tRNA splicing, depending on the dif-
f e r e n tt R N A :E . g .t R N A - P h ei su s u a l l yn o ta ss t r o n g l y
affected by mutations as tRNA-Tyr. Certain tRNA tran-
scripts are perhaps spliced more readily than other
tRNA transcripts [74]. This illustrates that it is difficult
to predict how mutations in the TSEN complex will
affect tRNA splicing in PCH patients. It is likely that
tRNA splicing activity in patients is reduced, and not
completely abolished as no patients to date have been
described with two nonsense mutations in one of the
TSEN subunits; this would abrogate tRNA splicing com-
pletely and lead to deprivation of certain amino acids,
which would be non-compatible with life.
Generally, PCH4 patients have a null allele and a mis-
sense mutation in TSEN54 and are therefore more
severely affected than PCH2 patients who carry two
missense mutations in TSEN54. This genotype-pheno-
type correlation suggests that loss of TSEN function is
the underlying disease mechanism in PCH2 and PCH4.
One could hypothesize that a defective TSEN complex
would lead to insufficient tRNA splicing, mainly affect-
ing intron-rich tRNA genes, like tRNA-Tyr (Table 4).
However Northern blot analysis of tRNA-Tyr from
fibroblasts of three patients homozygous for the com-
m o nm u t a t i o ni nTSEN54 did not show unspliced pro-
ducts. No significant difference was found in mature
tRNA-Tyr levels in fibroblasts of patients and controls
e i t h e r[ 3 7 ] .T os u m m a r i z e ,t h e r ei sn oe v i d e n c ef o ra
tRNA maturation defect in TSEN-mutated fibroblasts.
Neuronal cells derived from patients would be a better
substrate for tRNA maturation analysis, but unfortu-
nately brain material is scarce and usually severely
affected at the time of death. Induced pluripotent stem
cell (iPS) technology might circumvent this problem,
but even when patient fibroblasts can be converted to
neuronal cells, there is no guarantee that these cells will
show a phenotype. After all, not all neurons in a PCH
case are affected.
It remains possible that other unknown (cell type spe-
cific) functions of the TSEN complex may play a role in
the disease pathogenesis of PCH cases.
Zebrafish models of TSEN related PCH Recently we
established a zebrafish model for PCH. Knockdown of
tsen54 by antisense morpholino injections in zebrafish
embryos resulted in abnormalities in the mid-hindbrain
and a developmental delay. The zebrafish embryos
showed head hypoplasia and loss of structural integrity
in the brain. The loss of structural definition in the
brain is not due to a patterning defect, since fibroblast
growth factor 8 (Fgf8) and orthodenticle homeobox 2
(Otx2), two developmental markers, were expressed in
the correct regions. Instead the developing zebrafish
embryo’s showed increased levels of cell death, bearing
comparisons to the neurodegeneration observed in
PCH. This neurodegenerative phenotype is partially res-
cued by co-injecting human TSEN54 mRNA in zebrafish
embryos [81].
Expression analysis of tsen54 in zebrafish shows a ubi-
quitous expression pattern, but higher expression in
brain, primarily in the telencephalon and mid-hindbrain
boundary. This is in line with the expression of human
TSEN54 mRNA at eight weeks of gestation, in which
high expression in the developing telencephalon and
metencephalon is observed [81]. The human cerebellum
begins its development at six weeks of gestation and
continues growing into the postnatal period [82]. With
careful monitoring in PCH4/PCH5 cases, one can
already measure a decline in transverse cerebellar dia-
meter at 16 weeks of gestation, indicating a very early
onset of the neurodegeneration [11].
Antisense morpholino effects diminish after a few days
post-injection. Therefore we also developed a stable
tsen54 knockout zebrafish carrying a premature stop
codon. When bred to homozygosity these zebrafish
mutants were viable at 9 days post fertilization (dpf).
The absence of a major brain phenotype and survival up
to 9 –dpf may be explained by the presence of maternal
tsen54 during embryogenesis [81]. Redundancy of the
protein in zebrafish is not likely, as eventually these
mutant zebrafish die after 9 days.
RARS2 and PCH
RARS2, mutated in PCH6 and PCH1, is one of the 36
human tRNA synthetases. By the usage of ATP, the
tRNA synthetase binds to its cognate amino acid. This
complex of ATP, tRNA synthetase and amino acid,
binds to the appropriate tRNA whereto the amino acid
will be transferred (Figure 2B) [83]. RARS2 is involved
in the aminoacylation of arginine (Arg) to its mitochon-
drial- tRNA-Arg. In RARS2 mutated (c.110+5A > G)
fibroblasts, a reduction in the amount of the mt- tRNA-
Table 4 Overview of the number of human tRNA genes
with an intron and the remaining corresponding tRNAs
without an intron.
Human tRNA
species with
an intron
(anticodon)
Number of
human tRNA
genes with an
intron
Number of the remaining
human tRNA genes
without an intron (same
anticodon)
Pro - AGG 19
Arg - TCT 51
Leu - CAA 52
Ile - TAT 50
Tyr - ATA 10
Tyr - GTA 13 1
Cys - ACA 10
Trp - CCA 18
Adapted from the Genomic tRNA database [76].
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Page 10 of 14Arg was observed. Despite this reduction, the residual
mt- tRNA-Arg transcript was almost completely acy-
lated, suggesting that uncharged mt-tRNA-Arg tran-
scripts are unstable [12]. Morpholino-directed
knockdown of rars2 in zebrafish resulted in a similar
neurodegenerative phenotype as tsen54 knockdown,
suggesting the same pathogenesis for PCH2/4 and
PCH6, although it is still not understood how RARS2
is involved in the development of the pons and cere-
bellum [81].
Alternative functions of RARS2 compromising the
same biological pathway as the TSEN complex could
also be the underlying mechanism in PCH [73,78,81].
For some of the tRNA synthetases alternative functions
are known in processes like conventional splicing, apop-
tosis, viral assembly, regulation of transcriptional and
translational processes and angiogenic signaling [83-85].
SEPSECS and PCCA
Mutations in SEPSECS are associated with PCCA (pro-
gressive cerebello-cerebral atrophy). The SEPSECS
enzyme (Figure 2C) is involved in the final step of the
selenocysteine (Sec) synthesis [86,87]. Selenocysteine
lacks its own tRNA synthetase and in contrast to the
other amino acids selenocysteine is synthesized on its
cognate tRNA. The codon for selenocysteine is UGA,
normally encoding for translation termination, however
depending on the flanking sequences of the UGA, this
codon is recoded for a selenocysteine. Prior to seleno-
cysteine synthesis, serine (Ser) is aminoacylated to
tRNA-Sec by a seryl-tRNA synthetase; this Ser-tRNA-
Sec complex is then converted by a kinase to a Sep-
tRNA-Sec complex. As a final step SEPSECS converts
the Sep-tRNA-Sec to Sec-tRNA-Sec. It is not likely that
SEPSECS missense mutations (p.A239T, p.Y334K) com-
pletely abolish its function, as deprivation of selenocys-
teins is associated with lethality in mice [88].
Discussion
The identification of mutations in genes involved in
transcription and translation in neurological disorders
shows that these processes are important in (developing)
neurons [83,89-94]. The TSEN complex, RARS2 and
SEPSECS proteins, all share involvement in essential
processes in protein synthesis and mutations in the cor-
responding genes all lead to a severe phenotype of pon-
tocerebellar hypoplasia, often in combination with
cortical involvement. One explanation could be that
developing neuronal tissue is sensitive to dysregulation
of protein synthesis [83,92-94]. This hypothesis is sup-
ported by mice with a homozygous missense mutation
in the alanyl-tRNA synthetase gene (AARS). This mouse
has increased levels of mischarged tRNAs which lead to
intracellular accumulation of misfolded proteins in neu-
rons, this induces the unfolded protein response (UPR)
and these mice develop a neurodegenerative phenotype,
with Purkinje cell death and subsequent ataxia [95].
However UPR activation has not been detected in post-
mortem brain of PCH2 patients carrying a TSEN muta-
tion, but one can argue that UPR activation is an early
event in the pathogenesis of PCH and that postmortem
studies do not capture this event [19].
On the other hand it is possible that there is a time
frame during embryogenesis in which there is an extra
high demand for protein synthesis in neuronal tissue in
the early post-migratory stage. Human brain tissue
expresses relatively high overall levels of nuclear and
mitochondrial encoded tRNAs, which might be due to
higher levels of translation in the CNS compared to
other tissue [96]. Moreover, malnutrition in rats during
the prenatal period has severe consequences for brain
development and the cerebellum in particular [97]. Pro-
tein malnutrition both prenatally and postnatally, results
in reduced brain weight, thinner cerebral and cerebellar
cortices, reduced numbers of neurons, deficient myelina-
tion and reduced dendritic spines of cortical neurons
[98,99]. Therefore it is very likely that nutrients and
proteins are highly essential for normal brain
development.
Why mutations in other genes involved in protein
synthesis lead to completely different phenotypes
remains unclear. For example, mutations in other genes
involved in tRNA charging like KARS, YARS and GARS
lead to different types of Charcot-Marie-Tooth neuropa-
thy [83,100,101]. Mitochondrial aspartyl-tRNA synthe-
tase (DARS2) mutations cause leukoencephalopathy with
brain stem and spinal cord involvement and lactate ele-
vation (LBSL). Patients with LBSL have profound white
matter abnormalities in their cerebrum, pons and spinal
cord. There are some similarities between LBSL and
PCH, like cerebellar involvement and spasticity, but the
differences are more evident. Patients have slowly pro-
gressive cerebellar ataxia, dorsal column dysfunction,
occasionally a mild cognitive decline and the age of
onset is usually during childhood or even later. It is
unclear how mutations in DARS2 lead to LBSL [89].
Not all mutations in tRNA synthetase genes result in a
neurological phenotype. Missense mutations in the
mitochondrial Seryl-tRNA Synthetase gene (SARS2) give
rise to a multi-organ disease with Hyperuricemia, Pul-
monary Hypertension, Renal Failure and Alkalosis
(HUPRA-syndrome). Although there is failure to thrive
and a global developmental delay, patients exhibit no
neurological symptoms and brain ultrasound was
reported to be normal [102]. Compound heterozygote
mutations in mitochondrial histidyl-tRNA synthetase
gene (HARS2) were found in one family with ovarian
dysgenesis and progressive sensorineural hearing loss
(Perrault syndrome) [103].
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rological phenotype in the disorders described above is
that maturing neurons are more vulnerable for defects
in protein synthesis than other tissues, but this does not
explain the difference between disease presentation
shared by mutations of TSEN, RARS2 and SEPSECS,i n
which the cerebellum appears to be preferentially
affected and other diseases (KARS, YARS, GARS,
SARS2), with a different disease presentation.
Conclusions and Outlook
During the last decade many genes involved in protein
synthesis have been associated with different neurologi-
cal diseases. Several genes of PCH subtypes have been
described, in view of the shared function in tRNA pro-
cessing, a defect in protein synthesis seems the most
likely pathomechanism in PCH. Hopefully identification
of new genes in PCH subtypes will provide further
insight and lead us to a common disease pathway. Also
further research on TSEN and/or RARS2 function in
PCH models is necessary to elucidate the question why
solely the brain, and specifically the cerebellum and
pons are affected in PCH.
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